Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Obesity (Silver Spring). 2019 May;27(5):716–723. doi: 10.1002/oby.22444

Figure 2: Comorbidities were not associated with worse weight outcomes and obesogenic effect cannot be attributed to increased comorbidities.

Figure 2:

Odd ratio (OR) and 95% confidence interval (CI) of ≥5 percent total weight loss (%TWL) at the end of MOVE! program. P values from logistic regression adjusted for obesity pharmacotherapy and differences in baseline characteristics between responders and non-responders, including age, gender, obesogenic, Body Mass Index and leptogenic medications.